Treatment-related adverse events
| Adverse event . | |
|---|---|
| Neuropathy | 28 (42%) |
| PSN | 9 (13%) |
| PMN | 4 (6%) |
| Both PMN and PSN | 15 (22%) |
| Neutropenia | 20 (30%) |
| Thrombocytopenia | 8 (12%) |
| Anemia | 6 (9%) |
| Pulmonary toxicity | 6 (9%) |
| Transaminitis | 5 (7%) |
| Infusion reaction | 4 (6%) |
| Nausea/vomiting | 3 (4%) |
| Cardiotoxicity | 2 (3%) |
| Secondary malignancy | 1 (2%) |
| Adverse event . | |
|---|---|
| Neuropathy | 28 (42%) |
| PSN | 9 (13%) |
| PMN | 4 (6%) |
| Both PMN and PSN | 15 (22%) |
| Neutropenia | 20 (30%) |
| Thrombocytopenia | 8 (12%) |
| Anemia | 6 (9%) |
| Pulmonary toxicity | 6 (9%) |
| Transaminitis | 5 (7%) |
| Infusion reaction | 4 (6%) |
| Nausea/vomiting | 3 (4%) |
| Cardiotoxicity | 2 (3%) |
| Secondary malignancy | 1 (2%) |